The European Medicines Agency developed a continuity plan to handle the workload linked to the UK’s withdrawal from the European Union and the relocation of the EMA’s headquarters.

The plan aims to lessen disruptions to the assessment of products, while addressing possible losses in staff and other challenges. It categorizes and prioritizes tasks according to their impacts on public health and the agency’s ability to function.

The highest priority activities, in category 1, are directly related to product assessment and safety monitoring, including coordinating inspections across the EU or maintaining critical IT applications.